Should patients with heart failure listen to their gut?

John J Atherton and Chamindie Punyadeera
Med J Aust 2020; 213 (8): . || doi: 10.5694/mja2.50797
Published online: 19 October 2020

Dysregulation of the gut microbiota may be a target for novel therapeutic approaches

Large randomised, controlled studies have found that modulating dysregulated neurohormonal systems in patients with heart failure can reduce morbidity and mortality in those with a reduced left ventricular ejection fraction (LVEF).1 However, long term clinical outcomes remain poor, and most patients are unable to achieve the target doses of guideline‐directed therapy. Further, these drugs do not resolve all the pathophysiological perturbations associated with heart failure. Interest in biomarker discovery is therefore growing, not only to facilitate earlier diagnosis and risk stratification, but also to identify novel targets for therapeutic interventions.

  • John J Atherton1,2
  • Chamindie Punyadeera3

  • 1 Royal Brisbane and Women's Hospital, Brisbane, QLD
  • 2 University of Queensland, Brisbane, QLD
  • 3 Queensland University of Technology, Brisbane, QLD

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.